Search company, investor...

InnoLap Surgical

Stage

Other Investors | Alive

About InnoLap Surgical

InnoLap Surgical develops a device that leads to a new generation of scarless laparoscopic procedures. The device comprises a handle, thin 3 mm needle, and 5-10 mm detachable and replaceable operating heads (for example, graspers, scissors, dissectors). The InnoLap Surgical device utilizes a standard port and 3 mm needles inserted percutaneously. These extremely small punctures do not require stitches and do not leave scars.

Headquarters Location

Israel

Missing: InnoLap Surgical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: InnoLap Surgical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest InnoLap Surgical News

InnoLap Surgical Microlaparoscopy Technology Acquired by Teleflex

Oct 1, 2013

Oct 01, 2013, 08:00 ET from The Trendlines Group MISGAV, Israel, October 1, 2013 /PRNewswire/ -- Trendlines portfolio company established in mid-2012 identifies unmet need in minimally invasive procedures The Trendlines Group announces the acquisition of portfolio company InnoLap Surgical's technology by Teleflex, a global supplier of specialty medical devices for a range of procedures in critical care and surgery. Founded by CEO Yoni Epstein and Dr. Igor Igov in August 2012, InnoLap is an early-stage Israeli medical device company developing a microlaparoscopy platform for scarless laparoscopic procedures. The company's novel device reduces incision diameter, nearly eliminating the need for stitches and enabling surgeons the ability to perform scarless laparoscopic surgeries. "We are very pleased about this transaction with such a global leader as Teleflex," says Epstein. "We identified Teleflex as a potential partner very early in the process and understood their interest and strategic activity in the field of microlaparoscopy. " Epstein notes that InnoLap's success was very fast. "It was clear there was a huge clinical, aesthetic, and financial need for such a device. " Eran Feldhay, M.D., CEO of Trendlines Medical (Misgav), adds, "The purchase of such a young company as InnoLap is an impressive achievement and confirms both our investment strategy and process. " In the United States, an estimated 4 million laparoscopic procedures are performed annually. According to the Frost & Sullivan report, "U.S. Minimally Invasive and Laparoscopic Surgical Products," the U.S. laparoscopic resection device market is expected to reach sales of $775 million in 2014. About The Trendlines Group Trendlines ( http://www.trendlines.com ) creates and develops companies to improve the human condition. Partnering with passionate Israeli innovators, Trendlines invents, incubates, and invests in innovation-based, early-stage medical and agricultural technologies. Trendlines Medical, our investment unit for medical innovation, provides entrepreneurs with an environment that nurtures curiosity and leadership and presents investors with significant opportunities. For Media Relations: Ofir Shpigel Media and Public Relations +972-4-9535030

InnoLap Surgical Frequently Asked Questions (FAQ)

  • What is InnoLap Surgical's latest funding round?

    InnoLap Surgical's latest funding round is Other Investors.

  • Who are the investors of InnoLap Surgical?

    Investors of InnoLap Surgical include The Trendlines Group.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.